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Background: Chronic kidney disease is a significant contributor to mortality and morbidity worldwide, and the
number of people who require dialysis or transplantation continues to increase. People on dialysis are 15 times
more likely to die than the general population. Dialysis is also costly, intrusive, and time-consuming and imposes an
enormous burden on patients and their families. This escalating problem has spurred a proliferation of trials in
dialysis, yet health and quality of life remain poor. The reasons for this are complex and varied but are attributable
in part to problems in the design and reporting of studies, particularly outcome selection. Problems related to
outcomes include use of unvalidated surrogates, outcomes of little or no relevance to patients, highly variable
outcome selection limiting comparability across studies, and bias in reporting outcomes. The aim of the
Standardised Outcomes in Nephrology-Haemodialysis (SONG-HD) study is to establish a core outcome set for
haemodialysis trials, to improve the quality of reporting, and the relevance of trials conducted in people on
haemodialysis.
Methods/design: SONG-HD is a five-phase project that includes the following: a systematic review to identify
outcomes that have been reported in haemodialysis systematic reviews and trials; nominal group technique with
patients and caregivers to identify, rank, and describe reasons for their choices; qualitative stakeholder interviews
with patients, caregivers, clinicians, researchers, and policy makers to elicit individual values and perspectives on
outcomes for haemodialysis trials; a three-round Delphi survey with stakeholder groups to distil and generate a
prioritised list of core outcomes; and a consensus workshop to establish a core outcome set for haemodialysis trials.
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Discussion: Establishing a core outcome set to be consistently measured and reported in haemodialysis trials will
improve the integrity, transparency, usability, and contribution of research relevant to patients requiring haemodialysis;
ensure that outcomes of relevance to all stakeholders are consistently reported across trials; and mitigate against
outcome reporting bias. Ultimately, patients will be more protected from potential harm, patients and clinicians will be
better able to make informed decisions about treatment, and researchers and policy makers will be more able to
maximise the value of research to the public
Keywords: Core outcome set, Outcomes research, Patient-centred outcomes clinical trials, Dialysis, Haemodialysis,
Chronic kidney diseaseBackground
Chronic kidney disease (CKD) is a leading contributor
to mortality and morbidity [1–3]. Globally, the number
of people depending on kidney replacement therapy in
the form of kidney transplant or dialysis continues to in-
crease [4, 5]. Dialysis consumes a disproportionately
high proportion of the health-care budget in many coun-
tries [6–9]. Patients on dialysis have a 15 % annual mor-
tality rate, which is 15–100 times higher than that of the
general population [10–13]. Most patients receiving kid-
ney replacement therapy receive a form of dialysis, re-
quiring many hours of treatment each week. Patients
must also endure treatment burdens associated with
polypharmacy, invasive procedures, and difficult diet and
fluid restrictions, all of which profoundly disrupt nearly
all aspects of life. Studies have consistently shown that
patients requiring dialysis report a significant decre-
ment in quality of life, even lower than that reported
in patients with metastatic cancer and other chronic
diseases [14, 15].
This escalating burden has spurred an increase in ran-
domised trials and other forms of research in the dialysis
setting. From 2004 to 2014, 1500 reports of randomised
controlled trials (RCTs) (2000 including conference ab-
stracts) in haemodialysis were identified in the Cochrane
Renal Group Specialised Register [16]. Yet there has
been no substantial improvement in clinical, quality of
life, and mortality outcomes for patients on dialysis
[17, 18]. The reasons for this are multiple and complex
but may be attributed in part to fundamental problems
in the design and reporting of these studies, particularly
outcome selection. Problems relating to outcomes in-
clude highly variable outcome selection, outcome report-
ing bias, using outcomes of little patient relevance, and
the use of unvalidated surrogate outcomes [19–22].
Most trials that have assessed survival have not shown
significant improvements in mortality; and studies typic-
ally measure biochemical parameters, so it is unclear
whether the interventions improve outcomes that are
clinically relevant and important to patients.
Clinical trials aim to evaluate whether interventions
are safe and efficacious for patients by comparing theirrelative effects on outcomes chosen by the investigators.
The heterogeneity in outcomes measured and reported
in trials often renders the combination and comparison
of trial results impossible [23]. This creates difficulties in
interpreting the observed treatment effect and in making
evidence-based health-care decisions. For example,
standard approaches to evidence synthesis such as meta-
analysis cannot be used because of heterogeneity in trial
outcomes.
Outcome reporting bias can also threaten the validity
of meta-analysis and reliability of evidence [24, 25]. This
occurs when there is selective reporting within studies,
at the level of individual outcomes, based upon observed
favourable outcomes for the intervention [26]. Also,
omitting or inaccurately reporting outcomes, such as ad-
verse events, misleads and misinforms patients and clini-
cians, and this may result in patient harm.
A preoccupation with mortality may preclude study of
outcomes that are relevant to patients in living their life.
All researchers would regard mortality as an important
outcome, but an emphasis on mortality may detract
from other outcomes that impact a patient’s quality of
life. This is particularly important in a setting like dialy-
sis where very few interventions have been shown to im-
prove survival. The absence of mortality as a priority
outcome in research prioritisation activities undertaken
from patients’ perspectives has been observed in cancer,
mental health, and pulmonary disease [27, 28]. Two re-
search priority setting partnerships in CKD conducted in
Australia and Canada, patients, caregivers, and health
professionals participated in facilitated discussion and
prioritisation surveys to identify, rank and deliberate on
research priorities [29, 30] also found there was minimal
discussion about mortality. Outcomes determined to be
most relevant to the top 10 haemodialysis research ques-
tions included quality of life, satisfaction, anxiety, fatigue,
employment, interdialytic weight gain, and capacity for
self-management [29]. This strongly suggests that pa-
tients focus on living well with CKD rather than dying
from it.
Most studies do not report endpoints that are relevant,
meaningful, and important for patients, because patients
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stead, study investigators from academia and industry
typically define the outcomes to be measured in research
[22, 31]. Surrogate or composite endpoints based on in-
vestigators’ input are frequently selected in trials to re-
duce the cost, time, and sample size requirements and
to facilitate rapid market access of new drugs. There is
compelling evidence of the dangers of relying on surro-
gate endpoints in trials [32]. For example, erythropoietin
was approved to treat anaemia in patients with CKD on
the basis of improvements in haemoglobin, but targeting
normal haemoglobin levels was later found to increase
mortality [32, 33] but without a significant increase in
quality of life [34].
The lack of patient involvement in a research priority
setting in CKD in general and in establishing research
outcomes more specifically is problematic given the ob-
served mismatch of priorities between patients and clini-
cians in CKD [29, 35–39]. For example, patients on
dialysis are willing to sacrifice survival for freedom to
travel and prioritise caregiver respite [36, 37], outcomes
which are not “typically” assessed in research. Patients
attach a plethora of different values to outcomes, such
as empowerment, control, independence, social accept-
ance, family, guilt, normality, equity, freedom, flexibility,
productivity, and security [36, 40–44]. Patient-centred
care involves shared decision making and disease man-
agement between a patient and their clinician which take
into account the patient’s priorities and values and which
ultimately can encourage adherence to treatment and
improve patient-centred outcomes [45]. Delivering
patient-centred care requires an understanding of out-
comes that are important and relevant to patients.
In 2014, the Lancet reported that 85 % of the US$240
billion expended on health research in 2010 was wasted
because of problems in the design, conduct, analysis,
and reporting of research [20]. That article emphasised
that “waste is caused when potential users’ needs are ig-
nored” [20] (that is, when researchers do not assess the
effects of interventions in terms of functional, social,
and emotional well-being or adverse reactions and long-
term outcomes). This is important given that much of
research is publicly funded and that it is allocated with
the ultimate aim to improve the health and well-being of
populations.
Globally, there are increasing calls to develop core out-
come sets to ensure that trials include outcomes that are
relevant and important to stakeholders. The Outcome
Measures in Rheumatology (OMERACT) initiative was
formed in 1992 to identify and improve relevant health
outcome domains in rheumatology through an iterative
consensus process involving relevant stakeholder groups,
including patients [19, 46, 47]. OMERACT outcomes
have been endorsed by the World Health Organization(WHO) and the US Food and Drug Administration and
have improved the reporting and relevance of outcomes
in rheumatology trials [47, 48]. The OMERACT meth-
odology has been applied successfully in cancer [49], oti-
tis media [50], eczema [51], and chronic pain [52]. In
2010, the international Core Outcome Measures in Ef-
fectiveness Trials (COMET) organisation was launched
to facilitate the development and application of “core
outcome sets” [53, 54]. Core outcome sets represent the
minimum that should be measured and reported in all
clinical trials for a specific condition; however, they are
not meant to be definitive [53]. The intention is that the
core outcomes be collected and reported to allow the re-
sults of trials and other studies to be compared, con-
trasted, and combined as appropriate; researchers are at
liberty to collect and explore other outcomes. A core
outcome set does not exist for CKD.
This project will initially focus on haemodialysis as it
is the predominant dialysis treatment modality world-
wide. The ultimate aim of SONG is to develop a core out-
come set across the treatment spectrum of CKD, including
early-stage CKD (non-dialysis-dependent), haemodialysis,
peritoneal dialysis, and kidney transplantation. The specific
aim of SONG-HD is to establish a core outcome set which
is for haemodialysis trials and which will be used in other
forms of research. This is particularly important in CKD,
where registries of people on dialysis or who have been
transplanted are standard practice. To achieve this aim, the
following specific objectives will be addressed: (1) to de-
scribe the scope, quality, and consistency of outcomes used
in haemodialysis trials; (2) to identify outcomes that are im-
portant to patients, caregivers, clinicians, and policy
makers; (3) to ascertain the attitudes, values, and beliefs
underpinning their priorities for outcomes; (4) to generate
an evidence-informed, consensus-based prioritised list of
core outcome domains; and (5) to establish a core outcome
set for haemodialysis trials.Methods/design
SONG-HD is a five-phase multi-method project that in-
cludes systematic reviews, nominal group technique/
focus groups, semi-structured interviews, Delphi surveys
with best-worst/choice experiments, and a consensus
workshop. Our methodological framework is based on
validated processes developed by the OMERACT initia-
tive [19] that is endorsed by the WHO as a “successful
approach” for identifying core outcomes [55].Phase 1: Systematic review of outcome domains reported
in haemodialysis trials
A systematic review will identify and compare outcomes
reported in systematic reviews and RCTs of interven-
tions for adults on haemodialysis.
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A comprehensive search will be conducted in the
Cochrane Central Register of Controlled Trials without
time and language restrictions.
Types of studies and interventions
Cochrane systematic reviews and RCTs will be included.
For feasibility, the sampling frame for RCTs will be lim-
ited to RCTs included in published Cochrane systematic
reviews as data extraction will be conducted at the trial
level. Any intervention used to manage and treat pa-
tients on haemodialysis will be included.
Types of participants
Adult patients (age of at least 18 years) on
haemodialysis.
Exclusion criteria
Studies that exclude patients on haemodialysis.
Eligibility of studies
Two reviewers will independently assess all records ob-
tained. Full copies of all potentially relevant systematic
reviews and RCTs will be assessed independently by the
two reviewers, and any disagreement on the eligibility of
included studies will be resolved through discussion.
Assessment of methodological quality
An assessment of methodological quality will be under-
taken by using the Harman (2013) [50] appraisal framework
which addresses the rationale, selection, and reporting of
outcomes. This will be assessed independently by two
reviewers.
Data extraction
From each RCT, details of the author, year of publica-
tion, population (that is, only haemodialysis), number
and age of participants, and the intervention and com-
parator will be recorded. From each study, all outcomes
will be extracted by two authors. All outcomes will be
extracted unless it is specifically stated in the RCT that
the outcomes were measured and reported in the non-
HD patients only.
Data analysis and presentation
All eligible systematic reviews and RCTs will be tabu-
lated. The outcomes will be initially classified according
to the broad OMERACT categories of (i) mortality, (ii)
life impact, (iii) pathophysiological manifestations, (iv)
resource use and economic impact, and (v) toxicity, side
effects, and adverse events. Within each category, the
outcomes will be grouped into more specific outcome
domains. These domains will be reviewed by the Execu-
tive Committee to assess the appropriateness of thedomain name and grouping of outcomes. The frequency
of outcomes reported across systematic reviews and
RCTs will be assessed, and the scope and consistency of
outcome reporting will be evaluated.
Phase 2: Nominal group technique with patients and
caregivers
To ensure that patient-centred outcomes are identi-
fied, patients and caregivers will be asked to identify
and rank outcomes that are considered relevant and
important to them and to discuss reasons for their
choices. A combined focus group/nominal group
technique will ensure that the outcome domains im-
portant to the patients and caregivers be grounded in
their own accounts of what matters to them about
haemodialysis. The nominal group technique is a
transparent process of consensus development based
on structured group discussion [27, 56, 57]. This
technique is useful for generating ideas and priorities,
prevents dominant participants from controlling the
discussion, and allows participants the opportunity to
raise views and suggestions without direct criticism or
rejection of other participants [56].
Participants and recruitment
Patients and caregivers who have direct experience with
haemodialysis will be invited to participate. Approxi-
mately 12 nominal groups (involving 8–12 participants,
total n = 144) will be convened, though the final number
of groups will depend on when theoretical saturation,
defined as the point when few or no new outcomes or
issues are emerging, is reached. Participants will be re-
cruited from participating centres in Australia and
Canada in the first instance and purposively sampled to
achieve maximum diversity of demographic (age, gender,
socioeconomic status, ethnicity, location, and educa-
tional attainment) and clinical characteristics (in-centre
versus home haemodialysis, diagnosis, duration on dialy-
sis, wait-listing status, and comorbidities) to capture a
breadth of opinion. Informed consent will be obtained
from all participants.
Data collection
The nominal groups will be 2 hours in duration and
convened in a centrally located venue external to the
hospital to minimise the possibility of participants feel-
ing disempowered. All discussions will be audiotaped
and transcribed verbatim, and a researcher will record
the contextual details around the discussion. The ques-
tion guide will be developed from the guide we designed
to successfully elicit outcomes in kidney transplant re-
cipients [38] and includes the following:
i. Welcome and introduction (5 min)
Tong et al. Trials  (2015) 16:364 Page 5 of 9ii. Focus group discussion (45 min) – Participants will
deliberate and discuss experiences of HD and
perceived benefits, harms, and complications of
haemodialysis and haemodialysis-related
interventions.
iii. Nominal group technique (70 min) – Participants
will individually identify outcomes they believe are
important and relevant. These outcomes will be
written on the flipchart and then augmented with
outcomes identified from the systematic review
(phase 1) and in previous nominal groups. The list
of outcomes will be discussed and clarified. A copy
of the consolidated list will be printed for
participants to individually rank all of the outcomes
in order of perceived importance, from 1 (most
important) to X (least important). Similarities and
differences in ranking will be discussed among the
group.
Data analysis
Nominal group ranking: The highest ranked outcome
for each respondent will be assigned a value of 10
through to the least important, which will be assigned a
value of 1. Outcomes not ranked in the top 10 will be
assigned a value of zero. A mean priority score for each
outcome across all groups will be obtained by summing
ranking scores and dividing this by the maximum pos-
sible ranking score for that item. The maximum possible
ranking score for a given outcome will be calculated by
multiplying the number of participants who considered
the outcome by 10 (the maximum rank). If all partici-
pants who ranked an outcome scored it as the most im-
portant, the priority score is 100 %, whereas a score of
0 % means that all participants who ranked that out-
come did not score it in the top 10 most important out-
comes. Mean priority scores and the number of times an
outcome was voted in the top 10 will be calculated for
all participants. Mean priority scores will also be calcu-
lated separately for demographic and clinical characteris-
tics, and differences in mean scores will be assessed by
using analysis of variance.
Qualitative analysis: Using an adapted grounded theory
approach, as outlined by Corbin and Strauss [58], the
transcript will be imported into HyperRESEARCH and
reviewed line by line to identify concepts and themes,
compared within and across groups, and developed into
a coding scheme. The preliminary themes will be dis-
cussed with two other investigators to ensure that the
full range and depth of data are captured (investigator
triangulation). Through a process of constant compari-
sons between individuals and groups, analytical themes
will be developed. The final themes will reflect the be-
liefs, values, attitudes, and reasons underpinning the par-
ticipants’ choices and ranking of outcomes.Phase 3: Stakeholder interviews
Semi-structured interviews will be conducted to elicit a
range and depth of individual values, beliefs, and atti-
tudes toward outcomes, not to quantify frequency of
opinion [44, 59]. Reporting will be based on the Consoli-
dated Criteria for Reporting Qualitative Health Research
(COREQ) [60].
Participants and recruitment
Interviews will be conducted with the following stake-
holder groups internationally: (i) patients and caregivers,
(ii) health-care providers (nephrologists, surgeons,
nurses, psychologists, nurses, social workers, and dieti-
tians), and (iii) representatives from research, funding,
policy, industry, and other stakeholder organisations. A
minimum of 30 patients and 30 caregivers will be re-
cruited from participating centres and via consumer or-
ganisations worldwide (including Australia, Canada,
Europe, New Zealand, the UK, and the US). A minimum
of 60 health-care providers, policy makers, and health
professionals from national and international stake-
holder organisations will be identified from the investi-
gator’s networks. Participants will be “purposively”
identified to obtain a maximum variation of representa-
tion in demographics, clinical characteristics (patients),
and professional experience and responsibilities (health-
care providers and representatives from stakeholder or-
ganisations). Recruitment will continue until theoretical
saturation has been achieved in each stakeholder group.
Informed consent will be obtained from all participants.
Data collection
The interview guide will incorporate the results from the
systematic review and phase 2. Participants will be asked
to reflect and talk about (1) the experiences of living
with haemodialysis (patients) or caring for patients on
haemodialysis (caregivers/health-care providers), (2)
benefits and harms of haemodialysis/haemodialysis-re-
lated treatment, (3) outcomes believed to be relevant
and important to include in haemodialysis trials and
why, and (4) the results obtained in phase 2. Face-to-
face interviews will be conducted, but if this is not pos-
sible, Skype or telephone interviews will be conducted.
Each interview will be 30–45 min in duration, and all in-
terviews will be recorded and transcribed verbatim.
Data analysis
From the transcripts, a list of outcomes mentioned by
the participants will be extracted. Also, grounded theory
and thematic analysis (as detailed in phase 2) will be
used to analyze and describe the reasons for their prior-
ities, and a comparison will be made across stakeholder
groups.
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An international Delphi survey will be conducted to col-
lect opinions and distil the number of outcomes to a
prioritised list. The Delphi method is an iterative con-
sensus technique comprising sequential surveys an-
swered anonymously by a panel of participants with
relevant knowledge and expertise and gives equal influ-
ence to all who participate [57, 61].
Participants and recruitment
There is no standard sample size required in Delphi pro-
cesses, though Delphi studies in core outcome develop-
ment have reported participant numbers ranging from
13 to 222. For this study, the Delphi panel will include a
minimum target sample size of at least 400 respondents
with patients/caregivers comprising at least half of the
total sample size to ensure a numerical balance between
patients/caregivers and health professionals. Thus, the
aim is to recruit patients (n = 100), caregivers (n = 100),
clinicians (nephrologists [n = 100], vascular surgeons
[n = 20], and nurses [n = 20]), allied health professionals
(psychologists, social workers, and dieticians) (n = 20),
researchers (n = 20), and policy makers (n = 20), and re-
searchers and policy makers (n = 30). To ensure max-
imum variation in sampling, participants will be
recruited by using a similar strategy detailed in phase 3,
and approximately one third from each stakeholder
group with be recruited from participating countries/re-
gions, including Australia, the US, Canada, the UK, con-
tinental Europe, and Asia.
Participants will be recruited through participating
hospital/university institutions and patient/consumer or-
ganisations. All participants will be asked to register
their email on www.songinitiative.org prior to the survey
launch. Informed consent will be obtained from all
participants.
Data collection
The list of outcomes will be obtained from phases 1–3.
For feasibility, the outcomes will be listed individually
but grouped under a relevant domain. The survey will
be reviewed by the Executive Committee and piloted.
The surveys will be completed online by using a unique
identifier based on their name and email address to en-
able identification of participants completing all three
rounds of the Delphi survey. At least three reminders
will be sent to participants during the Delphi rounds.
Round 1: Participants will be asked to rate each of the
outcomes (approximately 30 outcomes) by using the
(GRADE) process, which recommends a nine-point
Likert scale to rank their importance [62]. Rankings of
7–9 indicate outcomes of critical importance, rankings
of 4–6 indicate outcomes that are important but not
critical, and rankings of 1–3 indicate outcomes oflimited importance. All outcomes will be randomised to
minimise ordering bias. Participants can suggest add-
itional outcomes and provide reasons for their rankings.
The additional outcomes will be re-coded and grouped
by two members of the investigator team (AT and RS)
and reviewed by the Executive Committee. All outcomes
will be carried through to round 2 with the distribution
of scores displayed for each outcome (rather than cutoff
scores) to avoid masking any major disagreement within
the group [61].
Round 2: Participants will review the group scores and
their own score for each outcome and will re-rank the
outcomes (including additional outcomes identified in
round 1) by using the nine-point scale and explain rea-
sons for any changes to their scoring.
Round 3: Participants will be shown their own score
and the distribution of scores for each outcome across
all stakeholder groups and for separate stakeholder
groups. A summary of the results from phases 2 and 3
will also be provided. Participants will be asked to re-
rank all outcomes and to indicate whether they should
be included in the core outcomes set. After the GRADE
rankings, a number of questions based on a novel prior-
ity setting approach using choice experiment methods
(for example, best-worst scaling (case 1) [63]) will also
be included. Participants will be presented with multiple
scenarios that present varying combinations of 4–5 out-
comes, developed by using a balanced incomplete block
design. They will choose the most important and least
important in each scenario. By presenting multiple sce-
narios to respondents, a full ranking of all attributes,
based upon the choices that respondents make, can be
estimated.Data analysis
For each outcome, the number of participants who
scored the outcome and the distribution of scores will
be summarised together. Results of the stakeholder
group responses will be compared with the whole group
response, and the percentage agreement will be used to
determine the structure and focus of the consensus con-
ference. Each outcome will be classified according to
Table 1. This pre-specified definition is used by OMER-
ACT and other similar initiatives [19, 50, 51] and mini-
mises the chance of consensus being defined post hoc in
such a way as to bias the results toward the beliefs of
the research team. The choice experiment questions will
be analysed initially by using a multinomial logit model
for all respondents and also by stakeholder group. More
complex model specifications such as a mixed logit
model [64], a generalised multinomial logit model [65],
or latent class models will also be examined. The overall
rankings of outcomes generated from this new method
Table 1 Delphi consensus definition
Consensus
in
Consensus that outcome
should be included in the
core outcome set
≥70 % participants scoring
as 7 to 9 AND <15 %
participants scoring as 1 to 3
Consensus
out
Consensus that outcome
should not be included in
the core outcomes set
≥70 % participants scoring
as 1 to 3 AND <15 % of
participants scoring as 7 to 9
No
consensus
Uncertainty about
importance of the outcome
Anything else
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the widely accepted Delphi approach.
Phase 5: Consensus workshop
A face-to-face consensus conference will be held for
stakeholders to review, comment on, and endorse the
core outcomes set. This conference will be chaired by
members of the Executive Committee. Approximately 60
participants will be invited and at least half will be pa-
tients/caregivers (n = 30). Other participants will include
nephrologists, nursing and allied health professionals, re-
searchers, and policy makers. This number is based on
the OMERACT consensus workshop. Purposive sam-
pling will be undertaken to ensure maximum variation
of demographic and clinical characteristics. Informed
consent will be obtained from all participants. All dis-
cussions will be audiotaped and transcribed. The confer-
ence program is outlined below, though details will
depend on the results obtained in phases 2–4.
1. Presentation of results: Detailed results from phases
2, 3, and 4 will be distributed to the participants
2 weeks prior to the conference to allow participants
time to reflect and enhance their ability to deliberate
and contribution to the discussions. The results will
be presented during a plenary session of the
consensus workshop, and the outcomes will also be
shown according to the consensus classification
(Table 1).
2. Breakout group discussion: Participants will be
divided into six groups of approximately 10
participants. A trained facilitator will moderate a
group discussion on the results from phases 3 and 4,
consensus classification of outcomes, similarities and
differences across stakeholder groups, and the
resolution of any disagreement, uncertainties, or
issues identified.
3. Plenary discussion: Each breakout group will present
a summary of their discussion. The conference chair
will moderate discussion.
4. Endorsement of core outcome set: Participants will
be asked to formally endorse (sign off ) the core
outcomes set, which will include the outcomes
classified as “consensus in”.Ethics
The Western Sydney Local Health District, Sydney, New
South Wales, Australia (HREC2009/6/4.15); Monash
Health, Melbourne, Victoria, Australia (13082B); the
University of Calgary, Calgary, AB, Canada (REB15-
0708); and the University of Sydney (2015/228) provided
ethical approval for this study.
Discussion
The international SONG-HD initiative will generate a
core outcome set for haemodialysis trials that is based
on the shared priorities of patients, clinicians, re-
searchers, policy makers, and relevant stakeholders. The
outcome domains will inform subsequent work in the
development of outcome measures (that is, specific tools
and thresholds) for evaluating outcomes that are mean-
ingful and relevant to users of the research, who are pri-
marily patients and their clinicians.
The core outcome set will be implemented in system-
atic reviews and trials via the investigator’s existing links
with international and national research and policy orga-
nisations. Specifically, this will be achieved by prioritis-
ing research that addresses core outcomes and
integrating core outcome sets into proposal and protocol
templates for trials, guidelines, and systematic reviews.
Thus, this project will improve the integrity, transpar-
ency, usability, and impact of research relevant to pa-
tients requiring haemodialysis; ensure that outcomes of
relevance to all stakeholders are consistently reported
across trials; and minimise outcome reporting bias. Ul-
timately, patients will be protected from potential harm,
patients and clinicians will be able to make informed de-
cisions about treatment, and researchers and policy
makers will be able maximise the value of research to
the public.
Trial status
Recruitment and data collection have commenced.
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